As part of Project Orbis, The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Oncotype DX® Breast Recurrence Scores from the National Cancer Database indicated that a lower threshold is needed for male patients with early stage ER-positive breast cancer to predict mortality.
MorphoSys announced that their ongoing phase III B-MIND study of tafasitamab passed the interim analysis for futility in patients with relapsed or refractory diffuse large B-cell lymphoma.
Samsung Bioepis announced that the FDA accepted a biologics license application for SB8, a biosimilar candidate for bevacizumab.
Myovant announced that their phase III HERO study of relugolix met its primary efficacy end point and all 6 secondary endpoints in men with advanced prostate cancer.
The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.
The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.
The MSK expert discusses exciting advancements in the field of immunotherapy for treating lung cancer at the Annual New York Lung Cancers Symposium®.
An international study of prostate cancer clinical trials discovered that opioid use appears to differ by region, implying that a variability should be considered.
Biomarker testing allows doctors to go beyond what’s under the microscope, helping to determine the best patient therapy.